Shield Therapeutics plc
("Shield" or the "Company" or the
"Group")
Notice of interim
results
London, UK, 14 August 2024: Shield
Therapeutics plc (LSE: STX), a commercial stage
pharmaceutical company that delivers Accrufer®/Feraccru® (ferric
maltol), an innovative and differentiated specialty pharmaceutical
product, to address a significant unmet
need for patients suffering from iron deficiency (with or without
anaemia), will announce its interim results for the six months
ended 30 June 2024 on Wednesday
4 September 2024.
Investor presentation
Interim CEO, Anders Lundstrom, and
CFO, Santosh Shanbhag, will be hosting a live online presentation
relating to the interim results via the Investor Meet Company
platform at 4.30pm (BST) on
Wednesday 4 September 2024.
The presentation is open to all
existing and potential investors. Questions can be submitted
pre-event via your Investor Meet Company dashboard up until 09.00am
(BST) the day before the meeting or at any time during the live
presentation.
Investors can sign up to Investor Meet Company for
free and add to meet Shield Therapeutics plc via:
https://www.investormeetcompany.com/shield-therapeutics-plc/register-investor
Investors who already follow Shield Therapeutics
plc on the Investor Meet Company platform will automatically be
invited.
For
further information please contact:
|
Shield Therapeutics plc
|
www.shieldtherapeutics.com
|
|
Anders Lundstrom, Interim
CEO
|
+44 (0)
191 511 8500
|
|
Santosh Shanbhag, CFO
|
|
|
Nominated Adviser and Joint Broker
|
|
|
Peel Hunt LLP
|
|
|
James Steel/Patrick
Birkholm
|
+44 (0)20
7418 8900
|
|
Joint Broker
Cavendish Ltd
Geoff Nash /
Rory Sale / Nigel Birks / Harriet Ward
|
+44 (0)20
7220 0500
|
|
|
|
|
Financial PR & IR Advisor
|
|
|
Walbrook PR
|
|
|
Charlotte Edgar / Alice Woodings
|
+44 (0)20
7933 8780 or shield@walbrookpr.com
|
|
|
|
About Iron Deficiency and
Accrufer®/Feraccru®
Clinically low iron levels (aka iron
deficiency, ID) can cause serious health problems for adults of all
ages, across multiple therapeutic areas. Together, ID and ID with
anaemia (IDA) affect about 20 million people in the U.S. and
represent a $2.3B market opportunity. As the first and only FDA
approved oral iron to treat ID/IDA, Accrufer® has the potential to
meet an important unmet medical need for both physicians and
patients.
Accrufer®/Feraccru® (ferric maltol)
is a novel, stable, non-salt-based oral therapy for adults with
ID/IDA. Accrufer®/Feraccru® has a novel
mechanism of absorption compared to other oral iron therapies and
has been shown to be an efficacious and well-tolerated therapy in a
range of clinical trials. More information about
Accrufer®/Feraccru®, including the product label, can be found
at: www.accrufer.com and www.feraccru.com.
About Shield Therapeutics
plc
Shield is a commercial-stage
specialty pharmaceutical company that delivers Accrufer®/Feraccru®
(ferric maltol), an innovative and differentiated pharmaceutical
product, to address a significant unmet need for patients suffering
from iron deficiency, with or without anaemia. The Company has launched Accrufer® in
the U.S. with an exclusive, multi-year commercial agreement with
Viatris Inc. (Viatris). Outside of the U.S., the Company has
licensed the rights to four specialty pharmaceutical companies.
Feraccru® is commercialised in the UK and European Union by Norgine
B.V. (Norgine), which also has marketing rights in Australia and
New Zealand. Shield also has an exclusive license agreement with
Beijing Aosaikang Pharmaceutical Co., Ltd. for the development and
commercialisation of Accrufer®/ Feraccru® in China, Hong Kong,
Macau and Taiwan; with Korea Pharma Co., Ltd. for the Republic of
Korea (Korea Pharma); and with KYE Pharmaceuticals Inc. for Canada.
To learn more about Shield Therapeutics, see our website
at www.shieldtherapeutics.com or
follow us on LinkedIn and X.
Accrufer®/Feraccru® has patent
coverage until the
mid-2030s.
Accrufer®/Feraccru® are registered
trademarks of Shield Therapeutics.